Mette Deleuran

Mette Deleuran
Aarhus University Hospital | AUH · Department of Dermatology

Chair, MD, DMSc

About

246
Publications
55,905
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
10,150
Citations
Citations since 2017
99 Research Items
6864 Citations
201720182019202020212022202302004006008001,0001,2001,400
201720182019202020212022202302004006008001,0001,2001,400
201720182019202020212022202302004006008001,0001,2001,400
201720182019202020212022202302004006008001,0001,2001,400
Additional affiliations
January 2016 - March 2016
Stanford Medicine
Position
  • Visiting Associate Professor
September 1999 - present
Aarhus University Hospital
Position
  • Professor (Associate)
July 1997 - December 1998
University of Southern Denmark
Position
  • Professor (Associate)

Publications

Publications (246)
Article
Background: Evaluation of effectiveness and safety of new systemic treatments for atopic dermatitis (AD) after approval is important. There are few published data exceeding 52-week therapy with dupilumab. Objectives: To examine the safety, effectiveness, and drug survival of dupilumab in a Danish nationwide cohort with moderate-to-severe AD up t...
Article
Full-text available
Background Patients suffering from Chronic Spontaneous Urticaria (CSU) may be recalcitrant to treatment with high dose second-generation antihistamines. These patients are, according to international guidelines, eligible to treatment with omalizumab. Treatment with omalizumab has proven to be very effective for this group of patients. Until 2018, w...
Article
The evidence‐ and consensus‐based guideline on atopic eczema was developed in accordance with the EuroGuiDerm Guideline and Consensus Statement Development Manual. Four consensus conferences were held between December 2020 and July 2021. Twenty‐nine experts (including clinicians and patient representatives) from 12 European countries participated....
Article
The evidence‐ and consensus‐based guideline on atopic eczema was developed in accordance with the EuroGuiDerm Guideline and Consensus Statement Development Manual. Four consensus conferences were held between December 2020 and July 2021. Twenty‐nine experts (including clinicians and patient representatives) from 12 European countries participated....
Article
Full-text available
Background: Paediatric atopic dermatitis (AD) can be burdensome, affecting mental health and impairing quality of life for children and caregivers. Comprehensive guidelines exist for managing paediatric AD, but practical guidance on using systemic therapy is limited, particularly for new therapies including biologics and Janus kinase (JAK) inhibit...
Article
Full-text available
Abstract Background Atopic dermatitis (AD) and chronic spontaneous urticaria (CSU) are two prevalent, visible and itching skin diseases associated with decreased quality of life (QoL), sleep disturbance, depression and anxiety. However, little is known about stigmatisation among patients suffering from these diseases. Objectives To examine whether...
Article
Full-text available
Purpose of Review Atopic dermatitis (AD) is a common, inflammatory, relapsing skin disease with intense itch. The disease affects approximately 20% of children and up to 10% of adults in affluent countries, however, the prevalence is fluctuating across the world and across ethnical groups. This review focuses on the epidermal barrier abnormalities...
Article
Objectives: Rheumatoid arthritis (RA) is a chronic autoimmune disease, that involves both pro- and anti-inflammatory mechanisms. The purpose of the present study is to investigate T-cell immunoglobulin and mucin domain 3 (Tim-3) in RA. Methods: Plasma levels of soluble (s) Tim-3 in early RA (n=98), were followed, to evaluate association with tre...
Article
Full-text available
Data from real-world use of new systemic treatments in atopic dermatitis (AD) is important for assessing safety and efficacy. The aim of this study is to de-scribe the baseline characteristics of adult patients with moderate-to-severe AD enrolled in the Danish nationwide Severe and ChRonic ATopic dermatitis CoHort (SCRATCH) database, between Octobe...
Article
Full-text available
Background: Moderate-to-severe atopic dermatitis (AD) often requires long-term management with systemic therapies. Objective: Our objective was to report the safety and efficacy of dupilumab treatment up to 4 years in adults with moderate-to-severe AD and efficacy in a subgroup of patients who transitioned from dupilumab once-weekly (qw) to admi...
Article
Atopic dermatitis (AD) is a chronic inflammatory skin condition that has a major impact on the quality of life of patients and their families. Therapeutic patient education (TPE) is recommended for all patients with this condition to improve disease management, adherence to therapy, and quality of life. Nurse‐led consultation, when performed by exp...
Article
Background: Chronic nodular prurigo (CNPG) is a chronic, inflammatory skin disease, characterized by intense and debilitating pruritus. The pathophysiology is not fully understood, and the condition is difficult to treat with no targeted therapies. The aim of this systematic review was to review the evidence of therapies for non-atopic CNPG and co...
Article
Background Abrocitinib efficacy by prior dupilumab response status in patients with moderate-to-severe atopic dermatitis (AD) has not previously been assessed in phase 3 studies. Objective Examine efficacy and safety of abrocitinib among patients who received prior dupilumab. Methods Patients with moderate-to-severe AD received abrocitinib 200 mg...
Article
Use of social media for online recruitment of clinical trial participants is a novel approach. However, little is known about the characteristics and costs of trial subjects recruited through social media. The aim of this study was to estimate the recruitment cost through Facebook and to present the characteristics of the recruited participants wit...
Article
Atopic dermatitis is a common inflammatory skin disease that can affect both children and adults. It is a chronic disease with recurrent, highly pruritic eczematous lesions. Topical treatment with anti-inflammatory agents is the mainstay of treatment for atopic dermatitis, either in a reactive or proactive approach according to severity of the dise...
Article
In chronic skin diseases such as atopic dermatitis (AD), therapeutic failure due to poor patient adherence to treatment is commonly reported. Therapeutic patient education (TPE) is an approach to improve self-management and adherence. Several studies demonstrated that TPE programmes have positive effects on disease management resulting in decreased...
Article
Full-text available
Background Systemic immunosuppressive treatments are central in the treatment of severe atopic dermatitis. Yet, comparative data are few on the performance of such immunosuppressive treatments in pediatric cohorts with severe atopic dermatitis. Objective To examine drug survival of systemic immunosuppressive treatments in a cohort of children with...
Article
Full-text available
IntroductionDupilumab is approved as first-line systemic treatment for adults/adolescents with moderate-to-severe atopic dermatitis (AD) in Europe and elsewhere owing to its favourable benefit–risk profile. However, systemic non-steroidal immunosuppressants (NSISS) are often used as first-line therapy in clinical practice. Impact of prior therapy w...
Article
Full-text available
Background Atopic dermatitis (AD) is a chronic, inflammatory skin disease that affects as many as 12.5% of children aged 0-17 years and 3% of the adult population. In the United States, 31.6 million children and adults are estimated to be living with AD. Objective Therapeutic patient education (TPE) has proven its value in the management of chroni...
Article
Full-text available
Immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome is a rare immune deficiency with a broad clinical presentation. IPEX syndrome causes dysfunctional regulatory T cells, increasing the risk of autoimmune diseases. In this case report, we describe a 7-year-old boy with lymphocytic interstitial pneumonia and bullous pemph...
Poster
Full-text available
Background: Thymus and activation-regulated chemokine (TARC) is a chemotactic factor for Th2 cells and eosinophils, which are important in atopic dermatitis (AD) pathogenesis. Serum TARC and total IgE levels correlate with AD disease severity. Dupilumab, a human monoclonal antibody, blocks the shared receptor component for interleukin (IL)-4 and IL...
Article
Full-text available
Importance: Atopic dermatitis (AD) may affect academic performance through multiple pathways, including poor concentration associated with itching, sleep deprivation, or adverse effects of medications. Because educational attainment is associated with health and well-being, any association with a prevalent condition such as AD is of major importan...
Article
Since the introduction of active vaccination against SARS‐CoV‐2 infection, there has been a debate about the risk of developing severe allergic or anaphylactic reactions among individuals with a history of allergy. Indeed, rare cases of severe allergic reactions have been reported in the United Kingdom and North America. By february 2021 a rate of...
Article
Full-text available
Atopic dermatitis is a heterogeneous disease and resists classification. In this review, we discuss atopic dermatitis nomenclature and identify morphologic phenotypes, which will facilitate correct diagnoses and development of treatment strategies. We support using the term ‘atopic dermatitis’ rather than eczema, because it describes the allergic b...
Article
Full-text available
The coronavirus disease 2019 (COVID-19) pandemic is caused by rapid spread of different strains of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The severity of infection ranges from mild, or even asymptomatic, to very severe. Signs and symptoms include fatigue, fever, exanthemas, upper respiratory illness, loss of smell and tas...
Article
Full-text available
Background: Most systemic agents used for moderate-to-severe atopic dermatitis (AD) may lead to adverse events requiring routine laboratory monitoring, increasing patient burden and possibly decreasing treatment adherence. Objective: To evaluate clinical laboratory findings in adults with moderate-to-severe AD treated with dupilumab up to 3 year...
Article
Currently no treat-to-target framework to guide systemic treatment in adults with moderate-to-severe atopic dermatitis exists. We sought to reach international consensus through an eDelphi process on a core set of recommendations for such an approach. Recommendations were developed by an international Steering Committee, spanning 3 areas (Guiding P...
Article
Full-text available
The aim of this appraisal of the literature is to elucidate the effects of immunosuppressive and immunomodulating agents used to treat atopic dermatitis (AD) on risk factors for fertility, pregnancy, and breastfeeding. Negative side effects of the psychological and physical stresses associated to AD flairs and uncontrolled AD are discussed, in orde...
Article
Full-text available
Atopic dermatitis (AD) is a highly pruritic, chronic inflammatory skin disease. The diagnosis is made using evaluated clinical criteria. Disease activity and burden are best measured with a composite score, assessing both objective and subjective symptoms, such as SCORing Atopic Dermatitis (SCORAD). AD management must take into account clinical and...
Article
Background Atopic dermatitis (AD) is a prevalent chronically relapsing inflammatory skin disease of childhood. However, little is known about self‐reported trigger factors, impact on daily life and factors associated with AD severity. Methods A nationwide questionnaire study of children in Denmark with hospital‐diagnosed AD in the time period 2014...
Article
Full-text available
IntroductionXerosis and pruritus are common manifestations of numerous dermatologic and systemic diseases. We evaluated the effectiveness of an emollient containing an Aquaphilus dolomiae extract (ADE-G1) for the management of pruritus and xerosis in patients of all age with a range of dermatologic and systemic diseases.Methods This open-label, rea...
Article
Full-text available
Background Management of moderate-to-severe atopic dermatitis (AD) commonly requires long-term treatment.Objective The aim of this study was to report the safety and efficacy of dupilumab treatment for up to 3 years in adults with moderate-to-severe AD.Methods This ongoing, multicenter, open-label extension study (LIBERTY AD OLE; NCT01949311) asses...
Article
Letters to the Editor should not have an abstract nor acknowledgements, should be formatted in one continuous section (no subheadings) and should not exceed 600 words, 10 references and a total of 2 figures; or 2 tables; or 1 figure and 1 table. No supplementary material (figure, table or text) is allowed when submitting a Letter to the Editor. All...
Article
Full-text available
特应性湿疹(也称为“特应性皮炎”或简称“湿疹”)是一种常见的皮肤病。大多数患有特应性湿疹的人可以通过局部治疗(直接涂抹在皮肤上)来控制湿疹,比如润肤剂和局部皮质类固醇。 然而,一些患有中度至重度疾病的患者,不能用这些疗法很好地治疗疾病。这些人需要使用片剂或注射剂进行全身药物治疗(作用于全身的治疗),以有效减轻他们的症状。 Dupilumab 是一种新的全身性药物 (自 2018 年以来), 用于治疗中度至重度湿疹患者。它已经在美国和欧盟获批用于治疗 12 岁或以上的患者。 为了比较 Dupilumab 与其他全身药物治疗的安全性,研究人员需要所有这些药物在实际应用中的安全性数据。TREAT 登记工作组的登记处收集了所有全身药物治疗特应性湿疹的有效性和安全性的数据。英国、爱尔兰、美国、德国、荷...
Article
Atopic eczema (also called ‘atopic dermatitis’ or just ‘eczema’) is a common skin disease. Most people with atopic eczema can control their eczema with topical therapies (applied directly to the skin) such as emollients and topical corticosteroids. Some people, however, have moderate‐to‐severe disease that cannot be well managed with those therapie...
Article
Full-text available
Background There are limited estimates of the incidence rates (IRs) of mastocytosis, and only a few studies have addressed the long-term consequences of living with these diagnoses. Previous reports have shown that systemic mastocytosis (SM) is associated with leukemic transformations and an increased risk of death as opposed to cutaneous mastocyto...
Article
Background: Dupilumab, a first-in-class therapy targeting the two key cytokines involved in the persistent underlying inflammatory pathway in atopic dermatitis (AD), is approved for treatment of moderate-to-severe AD in Europe, USA, Japan and several other countries. Objective: To assess dupilumab effects on SCORing Atopic Dermatitis (SCORAD) and c...
Article
Atopic dermatitis (AD) is a complex disease with elevated risk of respiratory comorbidities.1,2 Severely affected patients are often treated with immune‐modulating systemic drugs.3,4 On March 11th 2020, the World Health Organization declared the 2019 novel coronavirus severe acute respiratory syndrome (SARS‐Cov‐2) epidemic to be a pandemic. The num...
Article
Full-text available
Atopic dermatitis (AD) is a chronic, or chronically relapsing, inflammatory skin disease associated with asthma and allergic rhinitis, and is dominated by Th2 cells. The co-stimulatory T-cell receptor OX40 and its ligand, OX40L, play a central role in the pathogenesis of AD, as their interactions are crucial for the generation of TH2 memory cells....
Article
Full-text available
Background: For many years dermatologists have had access to few therapies for patients with moderate-to-severe atopic eczema (AE). New promising therapies are entering the market but conventional phototherapies and systemic therapies have more well-known safety-profiles, lower costs and wider availability. Objectives: To provide insight into cu...
Article
Full-text available
Background: Atopic dermatitis (AD) is a chronic skin condition where nonadherence often results in lack of disease control. Objective: We wanted to determine whether the combination of an electronic memory button and a supportive application (app) would affect the Quality of Life and subjective and objective severity measures among AD patients o...
Article
Full-text available
Background Filaggrin is a major structural protein in the skin barrier and null-mutations in the filaggrin gene (FLG) increase the risk of developing atopic dermatitis (AD). Previous studies report an association between keratoconus (KC) and the presence of AD, and FLG mutated patients with concomitant AD may have a more severe KC. We investigated...
Article
Linked Article: de Wijs et al. Br J Dermatol 2020; 182:418–426.
Article
Full-text available
Similarities and differences in the everyday clinical management of moderate-to-severe atopic dermatitis in Nordic countries are unknown. Using a modified Delphi approach, 15 dermatologists from Denmark, Finland, Norway and Sweden completed face-to-face and online questionnaires and participated in summary discussions to map expert opinion on the c...
Article
Full-text available
Patients with atopic dermatitis (AD) have an increased risk of bacterial skin infections that cause significant morbidity and, if untreated, may become systemic. Staphylococcus aureus (S. aureus) colonizes the skin of most AD subjects and is the most common organism to cause infections. Overt bacterial infection is easily recognised by the appearan...
Article
中重度特应性湿疹 (AE) 常通过光疗(光线治疗)或全身治疗(通过全身发挥作用的药物)来治疗。目前尚无关于这些治疗有效性和安全性的长期数据。为了解决这一问题,应在国家研究注册中收集正在现实生活环境中或曾经在此环境中使用这些治疗的儿童和成人患者的相关数据。理想情况下,这些国家注册应是可以相容的,从而可以合并尽可能多的患者数据,并加以分析(举例而言,这对于发现罕见副作用是必须的)。因此,所有国家都需要以相同方式收集相同的数据。为此,建立了国际特应性湿疹治疗 (TREAT) 注册任务组。它已经标准化了需要测量的项目(例如疾病严重程度、副作用)。这项研究解决了两个剩余问题:如何和何时测量这些项目。为了确定如何测量这些项目(即,使用何种测量工具),作者们使用了来自湿疹结局测量一致化 (HOME) 行动...
Article
Moderate‐to‐severe atopic eczema (AE) is often treated with phototherapy (light treatment) or systemic therapy (medication that works throughout the whole body). Long‐term data on effectiveness and safety of these treatments is currently missing. To address this issue, data on paediatric and adult patients who use or used these treatments in a real...
Article
Background: A long-term prospective observational safety study is essential to fully characterize the safety profile of systemic immunomodulating therapies for patients with atopic eczema. The TREatment of ATopic eczema (TREAT) Registry Taskforce offers a large platform to conduct such research using national registries that collect the same data...
Article
During recent years, cases involving terbinafine-resistant Trichophyton isolates have been increasingly reported, particularly in India. We present 14 cases of terbinafine treatment failure in Trichophyton infected Danish patients due to acquired resistance. Patients with Trichophyton rubrum (n=12) or Trichophyton interdigitale (n=2) infections wit...
Article
Full-text available
Background: Atopic dermatitis is characterized by chronic inflammation, which is a risk factor for atrial fibrillation. Objective: To examine the association between hospital-diagnosed atopic dermatitis and atrial fibrillation. Methods: Using linked population-based Danish registries, we identified persons with an inpatient or outpatient hospi...
Article
Full-text available
Background: Significant unmet need exists for long-term treatment of moderate to severe atopic dermatitis (AD). Objective: To assess the long-term safety and efficacy of dupilumab in patients with AD. Methods: This ongoing, multicenter, open-label extension study (NCT01949311) evaluated long-term dupilumab treatment in adults who had previousl...
Article
Full-text available
We present a case of severe and treatment-refractory bullous pemphigoid in a 3-month-old child. After topical and systemic corticoid treatment proved inefficient, dapsone 0.75 mg/kg was added initially without success. Disease control was reached with dapsone 1.5 mg/kg in addition to both topical and systemic glucocorticoid treatment, leaving the c...
Article
Atopic dermatitis (AD) is a common inflammatory skin disease that affects both children and adults, including a large number of adults of reproductive age. Several guidelines for the treatment of AD exist, yet specific recommendations for the treatment of pregnant or lactating women and for adults planning to have a child are often lacking. This po...
Conference Paper
Background Co-inhibitory receptors are important for the regulation of inflammation in autoimmune diseases. Among these, T-cell Immunoglobulin and mucin domain-3 (Tim-3) has recently gained attention, as it is expressed on exhausted T cells co-expressing PD-1 (1). Objectives To investigate Tim-3’s role in rheumatoid arthritis (RA). Methods Early...
Article
Full-text available
Background Patients with moderate-to-severe atopic dermatitis (AD) have increased infection risk, including skin infections and systemic infections. Immunomodulators (e.g., anti-tumor necrosis factors, anti-interleukin [anti-IL]-23, anti-IL-17, Janus kinase inhibitors) increase risk of infections. Dupilumab (a monoclonal antibody blocking the share...
Article
Full-text available
Background Conjunctivitis is common in patients with atopic dermatitis (AD) in general and a commonly reported adverse event in AD clinical trials with dupilumab. Objective To survey opinions and experience about conjunctivitis occurring in AD, including those during dupilumab treatment in a group of AD experts from the International Eczema Counci...
Article
特应性皮炎 (AE) 的严重程度有时候需要强效药物治疗,但尚无很多信息帮助医生选择正确治疗。不同药物的已公布试验难以评估,因为它们包括已精心选择的患者,并以不同方式测量疗效。在一个登记数据库中采集的在研究性试验以外实际使用这些药物的患者的数据可能提供更好的长期真实生活经验,前提是每个人都以相同方式(“结局指标”)报告他们的观察结果。在这项研究中,国际特应性湿疹治疗 (TREAT) 登记任务组实施了一项在线练习,以就应当测量和报告至 AE 登记数据库的最小变量集达成一致。向 36 个国家的 479 名参与者发送了 119 个可能项目的初始列表:主要是医生,还有护士、研究者、患者、行业和监管机构代表;86% 给出了答复,按从 0(不重要)到 9(非常重要)为各项目评分。通过另外两轮削减此列表;在...